KPV Peptide

Quick Summary

What it is. KPV is a tripeptide of three amino acids — lysine, proline, and valine — corresponding to the final three amino acids of alpha-melanocyte-stimulating hormone (α-MSH). It is the smallest peptide on the April 15, 2026 reclassification list.

Most-studied uses. Anti-inflammatory action in gastrointestinal conditions (ulcerative colitis and Crohn’s disease research models), atopic dermatitis and skin inflammation.

Current U.S. legal status (September 2026). Removed from FDA Category 2 on April 15, 2026. On July 23, 2026 the Pharmacy Compounding Advisory Committee recommended KPV for the 503A bulks list by 8–6 with one abstention (tally: Healio and CNN) — see the full PCAC outcome and what the vote means for patients. A recommendation is not approval: formal placement requires rulemaking, so prescription compounding through a licensed pharmacy remains the practical route.

Evidence base. Preclinical only. The mouse colitis literature is substantial and mechanistically coherent; no human clinical trial of KPV is registered on ClinicalTrials.gov as of September 15, 2026.

Expected post-PCAC price. $80–$180 for a 30-day oral capsule supply.

What is KPV?

KPV — lysine-proline-valine — is the C-terminal tripeptide of α-MSH, a 13-amino-acid peptide cleaved from proopiomelanocortin and best known for its role in pigmentation and immune modulation. KPV corresponds to its last three residues.

The fragment retains much of α-MSH’s anti-inflammatory activity without the pigmentary effect of the parent molecule, which is the observation that made it a research candidate. The mechanism proposed in the literature does not run through pigment-cell receptors: KPV suppresses pro-inflammatory signaling — reduced activation of NF-κB and MAP kinase pathways, and downstream reduction of cytokines including IL-6, IL-8 and TNF-α — rather than engaging melanocortin receptors the way full-length α-MSH does.

A second structural point matters for how it is used. At three residues, KPV is short enough to be a substrate for PepT1, the di- and tripeptide transporter on intestinal epithelium, which is what makes oral administration a plausible route in the research literature — with one important caveat covered below.

What the Research Shows

Gastrointestinal inflammation — the strongest evidence

KPV has more established preclinical work behind it than most peptides on the April 15 list. Its human evidence base, however, is empty:

• PepT1-mediated uptake in colitis models. The pivotal work (Dalmasso et al., Gastroenterology, 2007) showed that KPV is taken up through the PepT1 transporter and that this uptake reduces intestinal inflammation in a mouse colitis model. It established both the mechanism and the delivery route.
• DSS and TNBS colitis models in mice — orally administered KPV reduces colitis incidence and severity, inflammation markers and mucosal damage, tracked by reduced pro-inflammatory cytokine expression.
• Interleukin-10 deficient mouse models of chronic colitis — KPV administration reduces inflammation.
• Colon-targeted nanoparticle delivery (Molecular Therapy, 2017) — hyaluronic-acid-functionalized nanoparticles carrying KPV alleviated ulcerative colitis in mice more effectively than free KPV, evidence that delivery rather than pharmacology is the limiting step.

Why oral KPV is studied with a delivery vehicle

This is the most practically important nuance in the KPV literature, and most consumer-facing material skips it.

The PepT1 transporter that carries KPV across intestinal epithelium is expressed at low levels in normal colonic tissue and is up-regulated during inflammation, making the mechanism partly self-targeting. But it also means free KPV faces a transport bottleneck, and dietary amino acids compete for the same transporter. That is why much of the oral KPV research uses colon-targeted nanoparticle or hydrogel carriers rather than plain peptide: “oral KPV” in a mouse study often means KPV in a nanoparticle with colonic release, not KPV in a capsule.

Skin and inflammatory dermatologic conditions

KPV has been studied in atopic dermatitis models and in early topical formulations for inflammatory skin conditions. The mechanism overlaps with the GI work, and topical application avoids the intestinal transport question entirely. Human data for dermatologic use is, again, not available.

What’s less clear

KPV has been discussed in broader immune and longevity contexts. The evidence there is substantially weaker than for the GI and dermatologic indications, and there is no mechanistic story as clean as the PepT1 colitis work. If you encounter marketing positioning KPV as a general “immune peptide” or “longevity peptide,” treat that as overreach relative to the literature.

The evidence gap: no human trial has been registered

KPV’s evidence base stops at animal models, and that gap is worth stating plainly:

• A ClinicalTrials.gov search returns no registered study of KPV (checked September 15, 2026). There is no phase 1 safety study, no pharmacokinetic study in humans, and no interventional trial in ulcerative colitis or atopic dermatitis.
• The human literature is review-level, not trial-level. α-MSH and its related tripeptides are well reviewed — see the Endocrine Reviews 2008 survey — but a review of a mechanism is not evidence that a product works in patients.
• Claims about KPV in humans are extrapolation from mouse colitis models plus the assumption that PepT1 uptake behaves the same way in inflamed human colon. That assumption is reasonable; it is also untested.

What would close the gap: a phase 1 safety and pharmacokinetic study, then an induction trial in mild-to-moderate ulcerative colitis with endoscopic endpoints. Neither exists. Until they do, KPV sits with most of the April 15 list — mechanistically interesting, clinically unproven.

Legal and Regulatory Status

The April 15, 2026 reclassification

KPV was among the 12 peptides removed from FDA Category 2 on April 15, 2026, ending the enforcement posture that had treated them as effectively off-limits for compounding. The reclassification explainer covers what changed.

The July 2026 PCAC vote

The Pharmacy Compounding Advisory Committee reviewed seven of the twelve peptides on July 23–24, 2026 and recommended six — BPC-157, TB-500, KPV, MOTS-c, epitalon and semax — for the 503A bulks list, while declining to recommend emideltide (DSIP). KPV’s vote was 8–6 with one abstention (tally: Healio and CNN), among the closest of the six. The vote was per substance and per salt form, and it is advisory. Full vote breakdown and meeting outcome.

What comes next

Formal 503A bulks list placement requires notice-and-comment rulemaking, which the agency has historically taken months to years to complete. The near-term reality for the rest of 2026 is a hybrid: KPV is no longer Category 2, a federal advisory committee has recommended it for the bulks list, and compounding under prescription continues under enforcement discretion while rulemaking runs. The 2026 FDA peptide regulatory timeline tracks the sequence.

State-level variance

See the state-by-state tracker for your jurisdiction’s specific pharmacy compounding rules.

How It’s Typically Administered

Informational only; dosing is prescriber-determined.

KPV’s routes differ from most peptides on the April 15 list. Oral capsules are the most common format discussed for GI indications. Rectal suppositories are used for targeted colonic delivery in distal ulcerative colitis cases. Topical formulations are used for dermatologic indications. Subcutaneous injection is less common. As the delivery literature above shows, the route alone does not tell you whether a product delivers peptide to the tissue site.

Reported Safety Signals

The available literature — preclinical, plus the mechanistic review base — reports KPV as well-tolerated, with infrequent and mild adverse events in animal work. Because the tripeptide is short and closely resembles a fragment of a naturally occurring human peptide, its safety profile tends to look favorable relative to larger synthetic constructs.

The honest framing is stronger than “long-term data is limited”: for KPV there is no phase 1 human safety study at all, so the reported human safety record is clinical experience rather than systematically collected data. Supervised use by a licensed clinician is the standard for anything in this category.

What a prescriber will want to know

These are the questions a clinician evaluating a KPV request should be able to answer before prescribing. All are prescriber-facing; none is dosing advice.

1. What is the indication, specifically? KPV’s evidence is concentrated in GI and dermatologic inflammation. Requests framed as general “immune support” have no supporting literature.
2. Is the route matched to the evidence? The oral colitis evidence involves colon-targeted delivery systems, not plain capsules. A prescriber should know which format is being dispensed.
3. What does the compounding pharmacy document? Certificate of analysis, sterility and endotoxin testing, lot traceability — not optional for an injectable or rectally administered product. See the 10-point compounding pharmacy checklist.
4. What will be monitored, and by whom? With no human safety study, monitoring is the entire safety net, and reactions should be reported through FDA MedWatch as well as to the pharmacy.

Expected Pricing (Post-PCAC)

Format	Expected price range
Oral capsules (30-day supply)	$80–$180
Rectal suppositories	$100–$220
Topical formulation	$60–$140
Subcutaneous injection (5mg vial)	$120–$220

KPV has historically been less expensive than larger peptides like BPC-157 and TB-500 because its synthesis is simpler. Post-PCAC retail pricing should reflect this.

How to Source It Legitimately

Same framework as the rest of the April 15 peptides: prescriber → compounding pharmacy → COA-verified batch → supervision. Apply the 10-point pharmacy checklist.

A practical note for KPV specifically: for GI indications, your prescriber may well be a gastroenterologist or primary care clinician rather than a “peptide-focused” prescriber. That is a perfectly reasonable sourcing path.

Common Questions

Is KPV the same as alpha-MSH?

No. KPV is the C-terminal tripeptide fragment of α-MSH — its final three amino acids. It retains anti-inflammatory activity associated with the parent peptide but not its pigmentary activity, and it does not act through melanocortin receptors the way full-length α-MSH does.

Is KPV legal in 2026?

Yes, with the caveats that apply to the rest of the April 15 list. KPV came off FDA Category 2 on April 15, 2026, and PCAC recommended it for the 503A bulks list on July 23, 2026 by 8–6 (tally: Healio and CNN). A recommendation is not approval — compounding under prescription through a licensed compounding pharmacy is the route, and formal bulks list placement still requires rulemaking.

Has KPV been tested in humans?

No. ClinicalTrials.gov returns no registered KPV study as of September 15, 2026. The evidence base is mouse colitis models plus mechanistic reviews of α-MSH-related tripeptides.

Can KPV replace my ulcerative colitis medication?

No. KPV is studied as an adjunct in animal models, never as a replacement for standard-of-care therapy. Work with your gastroenterologist.

Is KPV safe?

Short-term animal use has been well tolerated, and the peptide resembles an endogenous human fragment. There is no human safety trial, so the reported human safety record is clinical experience rather than systematic data. Long-term human data does not exist.

Is oral KPV effective, or do I need injections?

The mouse colitis evidence for oral KPV uses colon-targeted delivery systems — in one well-cited study, hyaluronic-acid-functionalized nanoparticles — rather than plain peptide. That does not mean an oral product cannot work; it means the delivery format is part of the evidence, and a capsule is not automatically equivalent to what was studied.

What’s the difference between KPV and BPC-157 for gut issues?

They are distinct mechanisms with overlapping indications. BPC-157 is thought to support mucosal healing broadly; KPV more specifically modulates the inflammatory cascade through pathways including NF-κB. This is a prescriber call.

Primary sources

• Dalmasso G. et al., “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation,” Gastroenterology, 2007.
• “Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis,” Molecular Therapy, 2017.
• “Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo,” Endocrine Reviews, 2008.
• U.S. Food and Drug Administration, compounding inspections, recalls and other actions.
• ClinicalTrials.gov API search for “KPV” — zero registered studies, checked September 15, 2026.

Related Compounds

• BPC-157 — Alternative or complementary for GI and mucosal healing.
• TB-500 — Also PCAC-recommended in July 2026; different mechanism, tissue-repair focus.

---

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.